Abstract: The present specification provides an antisense oligonucleotide or a pharmaceutically acceptable salt or hydrate thereof targeting a particular region in genomic RNA of SARS-CoV-2, a pharmaceutical composition comprising the antisense oligonucleotide or the pharmaceutically acceptable salt or hydrate thereof, etc.

Abstract: A blood measurement device (10) includes a light emitting part (11) that emits a light beam that is to transmit through a measurement site (18), a light receiving part (19) that receives the light beam that has transmitted through the measurement site (18), an integrating sphere part (14) interposed in an optical path along which the light beam emitted from the light emitting part (11) reaches the light receiving part (19), the integrating sphere part (14) having formed inside a reflection surface (26) that reflects the light beam, a light entry part (23) which is an opening provided at the integrating sphere part (14) and through which the light beam applied from the light emitting part (11) enters an inside of the integrating sphere part (14), and a light exit part (16) which is an opening provided at the integrating sphere part (14) and through which the light beam reflected by the reflection surface (26) of the integrating sphere part (14) is emitted from the integrating sphere part (14) toward the measur

Abstract: Electromagnetic waves are uniformly distributed on the light-receiving surface side by taking advantage of their property of being easily concentrated in sharp parts, and the front area (SA) on the emission surface side is made larger than the back area (SB) on the light-receiving surface side (SA/SB>1), thereby forming a more moderate electric field region. A reduced gold fine particle group (average particle size: 20 nm) was self-assembled on a transparent polyester resin film and half-submerged and fixed. This base material was repeatedly immersed in an electroless gold plating solution so that gold particles were deposited on the gold fine particles. 10 microliters of a protein solution was added dropwise to this nanostructured substrate, and crystallized by a hanging drop vapor diffusion method.

Abstract: An object of the present invention is to provide an antiviral nucleic acid, etc. against SARS-COV-2 SARS-COV-2, SARS-COV-1, or MERS-COV and/or a method for treating and/or preventing viral infection using the nucleic acid, etc. The present invention relates to, for example, an antiviral nucleic acid or a pharmaceutically acceptable salt or hydrate thereof targeting a sequence in at least one target region selected from the group consisting of 5? UTR region, nsp3 region, 3C-like proteinase region, nsp9 region, RNA-dependent RNA polymerase region, helicase region, 3?-to-5? exonuclease region, 2?-O-ribose methyltransferase region, S region including S1 region and S2 region, E region, M region, and N region in genomic RNA of SARS-COV-2, wherein the virus is SARS-COV-2, SARS-COV-1, or MERS-COV.

Abstract: Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: A promoter on an AAV vector was changed to an Iba1 promoter, and a configuration that combined a miR-9 complementary sequence (miR-9T) and a miR-129 complementary sequence (miR-129T) was adopted. An exogenous gene was clarified to be efficiently and specifically expressed in microglia by using this vector, resulting in that an AAV vector that could efficiently and specifically express an exogenous gene in microglia of the central nervous system, was found.

Abstract: Provided is a motor control device capable of improving efficiency in real time by a neural network structure that directly derives, in a learning manner, an output signal providing optimal efficiency. A motor control device 1 is adapted to control a motor 6, and includes a neural network compensator 11 that receives input signals and repeats learning based on forward propagation and backpropagation thereby to derive an output signal providing optimal efficiency. Input signals are a motor current, a motor parameter and torque, and the like, and output signals are a current command value and a current phase command value. The motor 6 is controlled on the basis of an output signal derived by the neural network compensator 11.

Abstract: Fucosylated ?1-acid glycoprotein (fAGP) was found to be useful for the diagnosis of pancreatic cancer and malignant intraductal papillary mucinous neoplasm (IPMC), resulting in the finding of a new biomarker for pancreatic cancer or malignant intraductal papillary mucinous neoplasm (IPMC), in particular, a new biomarker useful for rapid diagnosis of malignant intraductal papillary mucinous neoplasm (IPMC) that increases the accuracy of malignant intraductal papillary mucinous neoplasm (IPMC) and aids conventional imaging diagnosis by making a suitable preoperative diagnosis of a benign neoplasm or a malignant neoplasm in intraductal papillary mucinous neoplasm (IPMN).

Abstract: A blood measurement device (10) includes a light emitting part (11) that emits a light beam that is to transmit through a measurement site (18), a light receiving part (19) that receives the light beam that has transmitted through the measurement site (18), an integrating sphere part (14) interposed in an optical path along which the light beam emitted from the light emitting part (11) reaches the light receiving part (19), the integrating sphere part (14) having formed inside a reflection surface (26) that reflects the light beam, a light entry part (23) which is an opening provided at the integrating sphere part (14) and through which the light beam applied from the light emitting part (11) enters an inside of the integrating sphere part (14), and a light exit part (16) which is an opening provided at the integrating sphere part (14) and through which the light beam reflected by the reflection surface (26) of the integrating sphere part (14) is emitted from the integrating sphere part (14) toward the measur

Abstract: It is an object of the present invention to provide a therapeutic drug for carcinomatous peritonitis. According to the present invention, a therapeutic drug for carcinomatous peritonitis which comprises an antibody which recognizes a transferrin receptor, is provided.

Abstract: Provided is a blood measurement device capable of accurately estimating the amount of a component contained in blood by passing light beams for calculating the amount of the component contained in blood along the same optical axis. A blood measurement device 10 of the present invention includes a light emitting part 11 having a first light emitting part 111 and a second light emitting part 112, a light receiving part 19, an actuator 16, and a computation and control part 17 that estimates a glucose level and controls operation of the actuator 16.

Abstract: A volumetric display capable of high-speed image presentation includes a resonance-type liquid lens having a focal length that is periodically adjusted using resonance of a liquid. An image projector projects an image toward a viewpoint position of a user via the resonance-type liquid lens. Further, the image projector projects an image toward the viewpoint position within a shorter time period than one-tenth of a variation cycle of the focal length. The image projector includes an LED and a DMD, for example.

Abstract: The present invention provides a novel nucleoside derivative or a salt thereof, a polynucleotide synthesis reagent, a method for producing a polynucleotide, a polynucleotide, and a method for producing a binding nucleic acid molecule. The nucleoside derivative or a salt thereof of the present invention is represented by the following chemical formula (1). In the chemical formula (1), Su is an atomic group having a sugar skeleton at a nucleoside residue or an atomic group having a sugar phosphate skeleton at a nucleotide residue, and may or may not have a protecting group, L1 and L2 are each independently a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms, X1 is an imino group (—NR1—), an ether group (—O—), or a thioether group (—S—), and R1 is a hydrogen atom or a straight-chain or branched, saturated or unsaturated hydrocarbon group having 2 to 10 carbon atoms.

Abstract: There is provided with a porphyrin compound represented by Formula (I) or a salt thereof; where A is a linking group represented as —X—NHCO— where X is a C1 to C6 alkylene group, each of R1, R2, R4, R5, R7, R8, R10, and R11 is a hydrogen atom, each of R3, R6, and R9 is a substituent of Formula; R12 is selected from a group of substituents represented by Formulae, R13 is a sulfo group, Ra, Rb, and Rc are substituents independently selected from C1 to C6 alkyl groups, and Rd is a hydrogen atom or a C1 to C6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.

Abstract: A DNA methylation editing kit comprises: (1) a fusion protein of inactivated CRISPR-associated endonuclease Cas9 (dCas9) having no nuclease activity and a tag peptide array in which plural tag peptides are linked by linkers, or an RNA or DNA coding therefor; (2) a fusion protein(s) of a tag peptide-binding portion and a methylase or demethylase, or an RNA(s) or DNA(s) coding therefor; and (3) a guide RNA(s) (gRNA(s)) comprising a sequence complementary to a DNA sequence within 1 kb of a desired site of methylation or demethylation, or a DNA(s) expressing the gRNA(s).

Abstract: The purpose of the present invention is to provide an injectable sol into a body, suited for delivery through a catheter, and usable for tissue perforation closure, ulcer protection, or vascular embolization. Provided are a sol for tissue perforation closure, a sol for ulcer protection, and a sol for vascular embolization, each containing from 0.6 mass % to 3 mass % of a collagen, water, from 200 mM to 330 mM sodium chloride, and a buffer and having a pH from 6.0 to 9.0.

Abstract: Provided is a method for efficiently manufacturing high-purity peripheral nerve cells from undifferentiated cells. The method for manufacturing peripheral nerve cells from undifferentiated cells having an ability to differentiate into peripheral nerve cells includes the following steps (a) and (b): (a) culturing undifferentiated cells having an ability to differentiate into peripheral nerve cells to induce differentiation into neural progenitor cells without detaching a grown colony from a culture vessel; and (b) detaching the neural progenitor cells produced in the step (a) from the culture vessel, then seeding the cells at a seeding density of 2×105 to 6×105 cells/cm2 to a culture vessel, and culturing the cells for 14 to 42 days.

Abstract: A method of producing a conditional knockout animal, and techniques related thereto, e.g., a method of efficiently producing a floxed animal, are provided. By introducing recombinase recognition sequences such as loxP into both ends of a target region on a chromosome at different timings, an animal having the pair of recombinase recognition sequences on the chromosome, such as a floxed animal, is produced.

Abstract: The present invention aims to develop a compound and a reagent having long phosphorescence lifetimes, for use in imaging of a hypoxic cell/tissue or for use in measurement/quantification of the oxygen concentration thereof. The present invention provides a reagent for measuring oxygen concentration, comprising a compound represented by the following General Formula (I) or (II). wherein R1 and R2 each independently represent hydrogen or a C1-C6 hydrocarbon group; and X? represents a counter anion.